Ustekinumab Biotherapy and Real-Time Psoriasis Capacitance Mapping: A Pilot Study
Figure 2
Relative area (means ± SD) of the PCM darker pixels in 5 psoriatic lesions from 5 patients (A to E) at inclusion and after a 1-month ustekinumab treatment. The global reduction in high capacitance inflammatory areas is significant ().
